Investment Rating - The report maintains a "Recommended" rating for the healthcare sector [7] Core Insights - The pharmaceutical sector has shown a slight outperformance against the CSI 300 index, with the Shenwan Pharmaceutical Bio Index rising by 1.16% from April 21 to April 25, 2025, outperforming the CSI 300 by 0.78 percentage points [2][12] - Year-to-date, the Shenwan Pharmaceutical Bio Index has decreased by 0.31%, yet it has outperformed the CSI 300 by 3.45 percentage points, ranking 13th among 31 Shenwan first-level industry indices [2][14] - As of April 25, 2025, the valuation of the pharmaceutical sector stands at 26.37 times (TTM overall method, excluding negative values), with a premium of 141.60% compared to the CSI 300 [2][17] Summary by Sections 1. Market Performance Review - The pharmaceutical sector has shown a mixed performance, with notable individual stock movements, including significant gains for companies like Yong'an Pharmaceutical (+31.37%) and Shutaishen (+28.41%), while companies like *ST Jiyuan experienced substantial declines (-43.24%) [3][18] 2. Important Policies and Events - On April 7, 2025, the Ministry of Commerce and the National Health Commission, among 12 departments, issued the "Special Action Plan to Promote Healthy Consumption," aimed at enhancing the quality of health goods and services to meet the public's needs [4][21] 3. Key Company Announcements - Companies such as Kanghong Pharmaceutical and Yiyue Medical have reported their 2024 annual results, with Kanghong achieving a revenue of 4.453 billion yuan, a year-on-year increase of 12.51%, while Yiyue reported a revenue of 7.566 billion yuan, a decline of 5.09% [22] 4. Industry Perspectives - The report highlights a continued rebound in the pharmaceutical sector, particularly in the innovative drug segment, which is expected to remain a key investment theme for 2025. The focus is shifting from earnings to fundamental changes in the industry and companies as the market enters a performance vacuum period starting in May [5][23][24]

本周永安药业、舒泰神和尔康制药等表现较好 [Table_Main] 行业研究|医疗保健 证券研究报告 医疗保健行业周报 2025 年 04 月 28 日 [Table_Title] 即将进入业绩真空期，关注基本面向上板块 ——医药生物行业周报（2025.4.21-2025.4.25） [Table_Summary] 报告要点： 医药板块本周小幅跑赢沪深 300 指数 2025 年 4 月 21 日至 4 月 25 日，申万医药生物指数上涨 1.16%，跑 赢沪深 300 指数 0.78pct，在 31 个申万一级行业指数中排名第 15。 2025 年初至今，申万医药生物指数下跌 0.31%，跑赢沪深 300 指数 3.45pct，涨跌幅在 31 个申万一级行业指数中排名第 13。截至 2025 年 4 月 25 日，医药板块估值为 26.37 倍（TTM 整体法，剔除负值）， 相对于沪深 300 估值溢价率为 141.60%。 医药行业政策风险，产品降价风险，研发进度不及预期风险。 [Table_Invest] 推荐|维持 [Table_ 过去一年PicQuote 市场行情] -19% -10% -1% 8% ...

Macro Strategy - The core viewpoint emphasizes the need for more proactive macro policies to stabilize the economy amid external shocks, with a focus on timely implementation of existing policies and introduction of new incremental policies [2][3] - The April Politburo meeting acknowledged the economic recovery but highlighted the necessity to solidify this foundation, especially in light of increasing external pressures [1][2] Fixed Income - The fixed income market is expected to remain in a narrow fluctuation pattern, with key observation points in May regarding potential reserve requirement ratio cuts [3][4] - The issuance of green bonds decreased significantly, with only 14 new bonds issued totaling approximately 10.87 billion yuan, while trading volume increased to 56.2 billion yuan [4] Company Analysis Arrow Home (001322) - The company faced demand pressure, with revenue expected to decline year-on-year in the first half of 2024, but a recovery is anticipated in the second half due to national subsidy policies [7] - Revenue from retail channels decreased due to intensified competition, while the home decoration channel showed growth [7] - The company is adjusting its strategy to focus on retail channels and enhance product strength and brand marketing [7] Nuotai Bio (688076) - The company reported a significant revenue increase of 57.21% in 2024, driven by the growth of peptide APIs [8] - The custom product segment also showed strong growth, with a notable order from a major European pharmaceutical company [8] - The forecast for net profit remains optimistic, with expected growth in the coming years [9] Taiji Group (600129) - The company experienced a substantial decline in revenue and net profit in Q1 2025, but there are signs of improvement compared to Q4 2024 [10] - The profit forecast for 2025-2026 has been adjusted downward due to ongoing market challenges [10] Guizhou Sanli (603439) - The company achieved a revenue increase of 31.16% in 2024, but faced a decline in net profit [11] - The forecast for net profit has been adjusted downward for 2025-2026, reflecting short-term pressures [11] National Grid Yingda (600517) - The company is pursuing dual development in finance and manufacturing, with a stable performance expected in 2024 [25] - The profit forecast for 2025-2027 has been slightly adjusted, but the long-term growth potential remains positive [25] Hengli Petrochemical (600346) - The company reported stable profitability despite industry competition, with a focus on optimizing operations and maintaining high dividend payouts [26][27] - The profit forecast for 2025-2026 has been adjusted downward, but the company continues to show growth potential [27] National Securities (600109) - The company reported a slight decline in revenue for 2024 but showed strong growth in Q1 2025 [28] - The profit forecast for 2025-2027 indicates a steady increase, supported by market reforms and economic recovery [28] Cambrian (688256) - The company achieved significant revenue growth in Q1 2025, driven by strong contributions from its largest customer [29] - The outlook for 2025 remains positive, with expectations for continued revenue growth and improved profitability [29] Giant Network (002558) - The company is actively expanding its AI capabilities, with a positive outlook for revenue growth in the coming years [30][31] - The profit forecast for 2025-2027 has been adjusted upward, reflecting a strong pipeline of new games [31]

具体到个股来看，融资余额出现增长的股票有1465只，占比39.69%，其中，201股融资余额增幅超过5% 。融资余额增幅最大的是常辅股份，该股最新融资余额1473.06万元，较前一交易日增幅达85.07%；股 价表现上，该股当日上涨2.08%，表现强于沪指；融资余额增幅较多的还有齐鲁华信、C江顺科，融资 余额增幅分别为68.52%、63.66%。 融资余额增幅前20只个股中，从市场表现来看，平均下跌1.72%，涨幅居前的有天富能源、振华股份、 许昌智能，涨幅分别为9.13%、7.31%、2.27%。跌幅居前的有苑东生物、C江顺科、科拜尔，跌幅分别 为11.80%、8.89%、7.50%。 融资余额增幅前20只个股 | 代码 | 简称 | 最新融资余额（万 | 较前一个交易日增减 | 当日涨跌幅（%） | 所属行业 | | --- | --- | --- | --- | --- | --- | | | | 元） | （%） | | | | 871396 | 常辅股 | 1473.06 | 85.07 | 2.08 | 机械设备 | | | 份 | | | | | | 830832 | 齐鲁华 信 | 820.9 ...

证券时报·数据宝统计显示，4月25日创业板指上涨0.59%，创业板股两融余额合计3368.58亿元，较上一 交易日减少9.75亿元，其中，融资余额合计3359.76亿元，环比上一日减少9.43亿元；融券余额8.82亿 元，环比减少3149.83万元。 创业板股最新融资余额为3359.76亿元，环比减少9.43亿元，20只股融资余额环比增长超10%，融资余额 环比降幅超10%的有14只。 具体来看，融资余额增长的创业板股有378只，其中，20股融资余额增幅超过10%。增幅最大的是力诺 药包，该股最新融资余额5973.59万元，环比上一交易日增幅为55.14%；股价表现上，该股当日下跌 5.51%，表现弱于创业板指；融资余额增幅较多的还有佐力药业、久祺股份等，分别增长50.43%、 36.86%。 融资余额环比下降的个股有558只，其中，降幅超过10%的有14只。华利集团融资余额降幅居首，最新 融资余额1.21亿元，环比下降35.83%；融资余额降幅较大的个股还有大叶股份、浙江华远等，融资余额 分别下降了24.60%、17.95%。（数据宝） 融资余额降幅居前个股 | 代码 | 简称 | 最新融资余额(万 | 融 ...

从所属行业来看，社保基金持股主要集中在电子、医药生物、计算机行业，分别有9只、6只、5只个股 上榜。 市场表现方面，获社保基金持有的科创板股4月以来平均下跌4.00%。从具体个股看，鼎阳科技累计涨 幅25.31%，表现最好，达梦数据、智明达等分别上涨9.08%、7.72%位居其后。跌幅最大的是聚和材 料，累计下跌17.71%。（数据宝） 社保基金持有的科创板股 财报季，社保基金持股动向曝光！一季度末社保基金共现身33只个股前十大流通股东榜，新进11只，增 持5只。 证券时报·数据宝统计显示，社保基金最新出现在33只科创板股前十大流通股东名单中，合计持股量1.33 亿股，期末持股市值合计59.74亿元。持股变动显示，新进11只，增持5只，减持8只，9只股持股量保持 不变。新进股中，盟科药业、新相微、泽璟制药等持股量居前。 社保基金持有科创板股中，从前十大流通股东名单中社保基金家数来看，社保基金家数最多的是英科再 生，共有4家社保基金出现在前十大流通股东名单中，即易方达基金管理有限公司-社保基金17042组 合、国泰基金管理有限公司-社保基金2103组合、全国社保基金一一二组合、全国社保基金一一一组 合，分别位列 ...

Core Insights - Pension funds have appeared in the top ten circulating shareholders of nine Sci-Tech Innovation Board stocks, with a total holding of 21.90 million shares valued at 862 million yuan at the end of the first quarter [1][2] - The pension funds have newly invested in two stocks, increased holdings in one stock, reduced holdings in two stocks, and maintained their positions in four stocks [1] Summary by Category Holdings Overview - The stock with the highest holding ratio by pension funds is Rongzhi Rixin, accounting for 4.53% of circulating shares, followed by Haitai Xinguang at 4.18% and Laisi Information at 2.71% [1] - The top three stocks by the number of shares held are Haitai Xinguang (5.04 million shares), Yubang Electric (3.74 million shares), and Rongzhi Rixin (3.70 million shares) [1] - The stocks with the highest market value held by pension funds are Rongzhi Rixin (194 million yuan), Haitai Xinguang (189 million yuan), and Laisi Information (150 million yuan) [1] Industry Focus - Pension fund holdings are primarily concentrated in the pharmaceutical and biotechnology, machinery equipment, and electric equipment industries, with two stocks from each sector represented [1] Performance Metrics - Among the stocks held by pension funds, seven reported year-on-year net profit growth in the first quarter, with Yubang Electric showing the highest increase of 168.08% [2] - The average decline of the Sci-Tech Innovation Board stocks held by pension funds since April is 3.52%, with Shihua Technology showing the best performance with a cumulative increase of 10.78% [2]

Core Insights - The social security fund has disclosed its stock holdings, appearing in the top ten shareholders of 57 stocks on the Sci-Tech Innovation Board, with a total holding of 279 million shares valued at 12.916 billion yuan [1][2] Group 1: Stock Holdings - The social security fund has newly entered 15 stocks and increased holdings in 16 stocks, while reducing holdings in 16 stocks, with 10 stocks remaining unchanged [1] - The stock with the highest holding ratio by the social security fund is Yingke Recycling, accounting for 7.11% of the circulating shares, followed by Hangcai Co., with a holding ratio of 6.24% [2] - The top five stocks held by the social security fund, each with over 10 million shares, include China Communication Signal, Transsion Holdings, and Western Superconducting, with holdings of 33.1432 million shares, 32.8289 million shares, and 27.6675 million shares respectively [2][3] Group 2: Performance and Profit Growth - Among the stocks held by the social security fund, 36 are expected to see year-on-year net profit growth in 2024, with the highest growth rate of 705.74% from Purun Co. [2] - The average increase in stock prices for the Sci-Tech Innovation Board stocks held by the social security fund this year is 2.57%, with the best performer being Shijia Photon, which has risen by 58.51% [3] Group 3: Industry Focus - The social security fund's holdings are primarily concentrated in the electronics, pharmaceutical, and computer industries, with 16, 8, and 8 stocks respectively [2]

作为私募基金行业的"顶流"，百亿元级私募机构的持仓情况备受市场关注。随着A股上市公司2025年一 季报陆续披露，多家百亿元级私募机构的最新持仓动向逐渐明晰。 深圳市前海排排网基金销售有限责任公司(以下简称"私募排排网")数据显示，按2025年4月27日已披露 2025年一季报的A股上市公司前十大流通股股东名单统计，已有23家百亿元级私募机构旗下产品现身96 家公司前十大流通股股东名单，合计持股市值达349.75亿元。 高毅资产持股市值第一 此外，上海通怡投资管理有限公司、上海迎水投资管理有限公司、珠海阿巴马私募基金投资管理有限公 司等知名私募机构旗下部分产品，也在多家上市公司前十大流通股股东名单中现身。 针对百亿元级私募机构在一季度积极调整投资布局，深圳市融智私募证券投资基金管理有限公司FOF基 金经理李春瑜对《证券日报》记者表示："这主要基于两方面考量：一方面缘于对未来市场走向的前瞻 性研判；另一方面是顺应政策环境与行业景气度的动态变化，通过深度挖掘行业与板块价值，捕捉结构 性投资机遇。" 前海钜阵资本管理(深圳)有限公司首席投资官龙舫在分析百亿元级私募机构调仓的投资逻辑时对《证券 日报》记者表示："配置调 ...

新股二级交投表现平淡，但首日交投情绪或有加速赶底迹象 新股专题 2025 年 04 月 27 日 策略类●证券研究报告 投资要点 新股周观点：上周，新股首日交投情绪出现明显降温，可能新股首日交投情绪正在 加速赶底。短期，按照正常的新股周期节奏，结合上周新股二级市场继续呈现出较 为克制的资金偏好属性，新股休整周期后段的震荡拉锯预计还将持续小段时间；但 即将步入 5 月，政治局会议上周落地及业绩即将披露完毕，外部环境或推动变化逐 渐出现；保持此前观点，谨慎之余或积极关注变盘信号及局部稀缺性标的活跃可能。 （1）新股次新板块出现剧烈震荡；假设以 2024 年以来上市的新股次新板块比较 来看，上周板块平均涨幅 0.6%，实现正收益占比约 62.2%。 （2）回顾上周市场表现，一方面新股二级交投市场继续维持此前交易周颇为谨慎 克制的交投氛围，短周期内不排除震荡拉锯还将持续小段时间；另一方面，新股首 日交投情绪则有加速赶底迹象，上周新股首日交投情绪大幅降温并触及去年 924 以来偏冷区位。短期来看，我们倾向于认为，虽然当前休整周期可能尚在后段，但 多个新股周期指标或正在重新寻求共振，随着时间推移，不排除本轮休整周期底部 ...